Editor

James J. Gillespie, Ph.D., is Editor of PharmaThought.com.  Dr. Gillespie is President and CEO of the Center for Healthcare Innovation (www.chisite.org), a not-for-profit thought-leadership organization focusing on the global life sciences industry.  He is a scholar, executive, and entrepreneur, with an expertise focusing on the strategy and operations of the biotechnology, medical device, nanotechnology, and pharmaceutical industries.  He serves on the Board of Directors for i.c.stars (Chair, Program Committee), and the Board of Directors of the America Israel Chamber of Commerce Chicago (First Vice President; Chair, Membership Committee).  Dr. Gillespie is President of the National Biotechnology & Pharmaceutical Association, the leading professional organization for African-Americans in the life sciences industry, and he is President the National Hispanic Life Sciences Society, a leading professional organization for Hispanic/Latino-Americans in the life sciences industry.  Dr. Gillespie leads the symposium “Globalization of Innovation: China, India, and US Pharmaceutical Markets” hosted by Microsoft Corporation.  His research has appeared in Academy of Management Review, European Journal of Social Psychology, Harvard Business Review, and Strategic Management Journal.  His education includes Northwestern University Kellogg School of Management, M.A., Ph.D.; Harvard University School of Law, J.D.; Princeton University Woodrow Wilson School of Public Policy, M.P.A.; Massachusetts Institute of Technology, B.S.; and Carnegie Mellon University.

Associate Editor

Charlotte Rocker is Associate Editor of PharmaThought.com.   Charolotte is an MS candidate in the Harvard-MIT Division of Health Sciences and Technology. In May 2011, she earned her MBA from MIT’s Sloan School of Management. Both degrees are part of the Sloan/HST Biomedical Enterprise Program (BEP), which aims to create the next generation of business leaders in the life sciences through an interdisciplinary curriculum of business, medical and entrepreneurship courses.  While at MIT, Charlotte interned with Booz and Company in their life sciences practice and with Edimer Pharmaceuticals, an early-stage orphan drug company based in Cambridge. Most recently, she spent the summer in Nairobi, Kenya building a market entry strategy for Daktari Diagnostics. Daktari is a US-based company developing a point-of-care CD4 monitoring system as an affordable, accessible alternative to flow cytometry in emerging markets.   Prior to MIT, Charlotte was an Assistant Science Director in Medical Strategy at Publicis Healthcare Communications Group, one of the world’s largest networks of pharmaceutical marketing, advertising and medical education agencies.Charlotte graduated with her BS in psychology from Brown University, where she worked as a clinical researcher at Rhode Island Hospital and volunteered as an Emergency Medical Technician for the university’s ambulance service.

India now in position of a thought leader on pharma patents: Kiran Mazumdar Shaw

Apr 19, 2013, 04.52AM 

(India is now in the position…)

By Kiran Mazumdar Shaw

Weeks after the Supreme Court ruling on Novartis AG's cancer drug, Glivec, one thing is clear: India is now in the position of a thought leader on pharmaceutical patents. But the country cannot afford to lose the moral high ground.

Therefore, just as India has set the bar on repetitive patenting, it cannot be seen as being guilty of condoning patent law violations. India should ensure that it does not violate any multilateral trade agreements when invoking tools like compulsory licensing for ensuring affordability of patented innovator drugs.